Shoulder Innovations, Inc. (SI)
NYSEHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$20.32-0.34%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - SpecialtiesSnapshot 2026-09-04
QuarterlyIQ Insights · SI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Drive net revenue growth for full year 2026 to reach $67 million to $69 million, representing 42% to 46% growth over 2025.
Stated as a priority in 3 of last 3 quarters. Net revenue grew from $10.1 million in 2025-Q1 to $17.2 million in 2026-Q2, a 56-65% increase quarter-over-quarter. Management raised full year 2026 revenue guidance twice, now targeting $67 million to $69 million, representing 42% to 46% growth over 2025. The trajectory is delivering consistent strong growth and upward guidance revisions.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Increased full year 2026 net revenue guidance to $67 million to $69 million, representing growth of approximately 42% to 46% over full year 2025 net revenue.”
“Raised full year 2026 net revenue guidance to $65 million to $68 million, representing growth of approximately 37% to 44% over full year 2025 net revenue.”
“Initiated full year 2026 net revenue guidance of $62 million to $65 million, representing growth of approximately 31% to 37% over full year 2025 net revenue.”
Focus on controlling operating losses and improving operating income despite increased expenses from commercial expansion and R&D.
Stated in 2 of last 3 quarters. Operating losses increased from $4.3 million in 2025-Q1 to $9.0 million in 2026-Q1 and $10.0 million in 2026-Q2, driven by investments in commercial expansion and R&D. Despite increased losses, management continues to emphasize managing these losses as part of growth strategy. The trajectory shows increased losses consistent with stated priorities.
“Operating loss in the second quarter of 2026 was $10.0 million, compared to a loss of $5.9 million in the second quarter of 2025.”
“Operating loss in the first quarter of 2026 was $9.0 million, compared to a loss of $4.3 million in the first quarter of 2025.”
Maintain liquidity and cash flow management, including refinancing debt and securing new credit facilities to support growth.
Stated in 2 of last 3 quarters. Management secured new credit facilities totaling up to $50 million in 2026-Q2, refinancing prior debt and increasing liquidity. Cash and equivalents plus marketable securities decreased from $108.5 million in 2026-Q1 to $99.0 million in 2026-Q2, reflecting cash usage. The trajectory shows active liquidity management aligned with stated priorities.
“Closed two new credit facilities for up to $50 million with Stifel Venture Banking, refinancing existing debt and adding undrawn working capital capacity.”
“Entered into Loan and Security Agreement with Stifel Bank for a senior secured term loan of $15 million and revolving credit facility.”
Expand operational capacity by leasing a new commercial building with office and warehouse space.
Newly stated in 2026-Q1. Management announced a lease agreement for a new 15,200 square foot commercial building to expand facilities. No subsequent updates on progress or financial impact are available. The priority is recent with limited delivery evidence so far.
“Entered into a lease agreement for a new commercial building of approximately 15,200 square feet with office and warehouse space.”
Complete full commercial launch and drive adoption of the InSet I-135RFX Humeral Stem product in the market.
Newly stated in 2026-Q1. Management announced the full commercial launch of the InSet I-135RFX Humeral Stem product. No quantitative sales or adoption metrics have been provided yet. The priority is recent with limited delivery evidence so far.
“Initiated full commercial launch of the InSet I-135RFX Humeral Stem following successful limited user release and FDA clearance.”
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity, the US dollar (low R² over the window).
7 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.